A review on liposome-based therapeutic approaches against malignant melanoma.
Drug delivery
Liposome
Melanoma
Nanotechnology
Journal
International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127
Informations de publication
Date de publication:
15 Apr 2021
15 Apr 2021
Historique:
received:
13
11
2020
revised:
10
02
2021
accepted:
17
02
2021
pubmed:
6
3
2021
medline:
22
6
2021
entrez:
5
3
2021
Statut:
ppublish
Résumé
Melanoma is a highly aggressive form of skin cancer with a very poor prognosis and excessive resistance to current conventional treatments. Recently, the application of the liposomal delivery system in the management of skin melanoma has been widely investigated. Liposomal nanocarriers are biocompatible and less toxic to host cells, enabling the efficient and safe delivery of different therapeutic agents into the tumor site and further promoting their antitumor activities. Therefore, the liposomal delivery system effectively increases the success of current melanoma therapies and overcomes resistance. In this review, we present an overview of liposome-based targeted drug delivery methods and highlight recent advances towards the development of liposome-based carriers for therapeutic genes. We also discuss the new insights regarding the efficacy and clinical significance of combinatorial treatment of liposomal formulations with immunotherapy and conventional therapies in melanoma patients for a better understanding and successfully managing cancer.
Identifiants
pubmed: 33667562
pii: S0378-5173(21)00217-9
doi: 10.1016/j.ijpharm.2021.120413
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Liposomes
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
120413Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.